FK866 previously showed anti-fibrosis and antioxidant effects through maintenance of NAD+ homeostasis during diabetic nephropathy 56, while NAMPT inhibitors were developed for treating cancer, their anti-cancer effects are dose-dependent. This evidence concerns the gene NAMPT and cancer.